Intra-Cellular Therapies (ITCI): Parkinson's Disease Drug Expansion Could Be The Next Move
Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study. Read why ITCI stock is a Strong Bu...
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...
Read More
Other Stories in Business
- Intra-Cellular Therapies (ITCI): Parkinson's Disease Drug Expansion Could Be The Next Move
- Juan Soto’s $765M deal with the Mets is the largest in MLB history. Here’s who he passed
- Trump nominates ex-ambassador to Mexico to serve as deputy secretary of State
- Complete Berachain Airdrop Guide: Get Free Tokens
- Claim MemeFi Coin Airdrop — Free Crypto Distribution
- 5 AI-Powered Programming Tools You Should Know About
- HALFTURN - Horror Film
- IWF May Struggle To Sustain Its Robust Return In 2025, But IWD Could Shine
- Average people hobbies vs Rich people Hobbies
